Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Healios K.K. (4593:JPX), powered by AI.
Healios K.K. is currently trading at ¥255. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Healios K.K. on Alpha Lenz.
Healios K.K.'s P/E ratio is -12.4.
“Healios K.K. trades at a P/E of -12.4 (undervalued) with modest ROE of -63.8%.”
Ask for details →Healios K.K., a pioneering company in the field of biotechnology and regenerative medicine, focuses on advancing therapeutic solutions by leveraging stem cell technologies. Established in Japan, Healios K.K. seeks to address critical medical needs by developing innovative treatments, particularly in the areas of ophthalmology and organ regeneration. Its core initiatives include the development of cellular therapies to combat degenerative diseases and restore function where traditional medicine has limited efficacy. With strategic collaborations and cutting-edge research, Healios K.K. has positioned itself as a key player in the life sciences sector. The company not only contributes to the scientific community through its research and development efforts but also impacts the broader healthcare industry by exploring novel therapeutic options. Healios K.K.'s work stands at the frontlines of scientific discovery, aiming to transform patient care and improve quality of life for individuals suffering from chronic and life-altering conditions.
“Healios K.K. trades at a P/E of -12.4 (undervalued) with modest ROE of -63.8%.”
Ask for details →Healios K.K. (ticker: 4593) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 65 employees. Market cap is $27.5B.
The current price is 255 with a P/E ratio of -12.38x and P/B of 5.61x.
ROE is -63.77% and operating margin is -3211.54%. Annual revenue is $104M.